相关实验视频
Updated: Jul 17, 2025

09:47
Isolation, Processing and Analysis of Murine Gingival Cells
Published on: July 2, 2013
19.1K
高血糖症通过促进巨细胞中SETDB1-介导的LINE-1去抑制来加剧牙周炎症-衰老
Ziqi Yue1,2, Luningxiao Nie1,2, Ning Ji1
1State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.
Journal of clinical periodontology
|September 3, 2023
概括
高血糖 (高血糖) 通过影响巨细胞,使牙疾病 (牙周炎症-衰老) 恶化. SET域分叉的基因组氨酸甲基转移酶1 (SETDB1) 是关键的,其恢复可能治疗与糖尿病相关的牙问题.
科学领域:
- 牙周病学 牙周病学
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
背景情况:
- 高血糖症与牙周病有关.
- 巨细胞表型变化可能会调解这种联系.
- 在SET域分叉的基因组氨酸甲基转移酶1 (SETDB1) 的作用尚未被探索.
研究的目的:
- 调查高糖血症是否会诱导巨细胞的表型转变,从而导致牙周炎症-衰老.
- 探索涉及 SET 域分叉的 ヒ斯 lysine 甲基转移酶 1 (SETDB1) 的潜在机制.
主要方法:
- 建立了一个高血糖性小鼠模型,并分析了牙周组织.
- 用于不同葡萄糖度的体外巨细胞培养物.
- 采用siRNA和过度表达等离子体来研究SETDB1在巨衰老和炎症衰老中的作用.
- 在人类牙组织中检查了SETDB1和LINE-1表达.
主要成果:
- 在糖尿病患者和小鼠的牙周组织中,SETDB1的表达减少.
- 在糖尿病小鼠中,SETDB1缺乏促进了巨细胞衰老,加剧了牙周炎症衰老.
- 甲胺治疗恢复了SETDB1活性,并改善了高血糖引起的牙周炎症-衰老.
结论:
- SETDB1调节了巨细胞的衰老类切换.
- SETDB1是糖尿病引起的牙周炎症-衰老的潜在治疗标.
相关概念视频
Hypoglycemia and Glucagon
295
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
295
Oral Hypoglycemic Agents: Biguanides and Glitazones
230
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
230
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
205
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
205
Pathophysiology of Diabetes
986
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
986
Diabetes: Symptoms, Diagnosis, and Complications
588
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
588
Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211

